Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma.

Wu F, Shi X, Zhang R, Tian Y, Wang X, Wei C, Li D, Li X, Kong X, Liu Y, Guo W, Guo Y, Zhou H.

Cell Death Dis. 2018 May 11;9(5):564. doi: 10.1038/s41419-018-0618-6.

2.

Unusual and Interesting Adverse Cutaneous Drug Reactions.

Masatkar V, Nagure A, Gupta LK.

Indian J Dermatol. 2018 Mar-Apr;63(2):107-116. doi: 10.4103/ijd.IJD_584_17.

3.

Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma.

Franco AI, Eastwick G, Farah R, Heyboer M, Lee M, Aridgides P.

Case Rep Dermatol Med. 2018 Feb 21;2018:2354146. doi: 10.1155/2018/2354146. eCollection 2018.

4.

Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment.

Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY.

Stem Cells Int. 2018 Feb 28;2018:5416923. doi: 10.1155/2018/5416923. eCollection 2018. Review.

5.

Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies.

Leprieur EG, Jablons DM, He B.

Oncotarget. 2018 Feb 6;9(18):14680-14691. doi: 10.18632/oncotarget.24411. eCollection 2018 Mar 6. Review.

6.

Locally Advanced Basal Cell Carcinoma with Intraocular Invasion.

Tchernev G, Lotti T, Lozev I, Maximov GK, Wollina U.

Open Access Maced J Med Sci. 2018 Jan 13;6(1):126-127. doi: 10.3889/oamjms.2018.012. eCollection 2018 Jan 25.

7.

Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.

Whitson RJ, Lee A, Urman NM, Mirza A, Yao CY, Brown AS, Li JR, Shankar G, Fry MA, Atwood SX, Lee EY, Hollmig ST, Aasi SZ, Sarin KY, Scott MP, Epstein EH Jr, Tang JY, Oro AE.

Nat Med. 2018 Mar;24(3):271-281. doi: 10.1038/nm.4476. Epub 2018 Feb 5.

PMID:
29400712
8.

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Oncoimmunology. 2017 Dec 22;7(3):e1404217. doi: 10.1080/2162402X.2017.1404217. eCollection 2018.

9.

Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma.

Eberl M, Mangelberger D, Swanson JB, Verhaegen ME, Harms PW, Frohm ML, Dlugosz AA, Wong SY.

Cancer Cell. 2018 Feb 12;33(2):229-243.e4. doi: 10.1016/j.ccell.2017.12.015. Epub 2018 Jan 27.

PMID:
29395868
10.

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib.

Yoon J, Apicelli AJ 3rd, Pavlopoulos TV.

JAAD Case Rep. 2017 Dec 18;4(1):10-12. doi: 10.1016/j.jdcr.2017.11.001. eCollection 2018 Jan. No abstract available.

11.

Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib.

Miedema J, Meyers MO, Zedek D, Roughton MC, Jolly PS.

JAAD Case Rep. 2017 Dec 18;4(1):24-26. doi: 10.1016/j.jdcr.2017.07.025. eCollection 2018 Jan. No abstract available.

12.

Neuronal delivery of Hedgehog directs spatial patterning of taste organ regeneration.

Lu WJ, Mann RK, Nguyen A, Bi T, Silverstein M, Tang JY, Chen X, Beachy PA.

Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E200-E209. doi: 10.1073/pnas.1719109115. Epub 2017 Dec 26.

PMID:
29279401
13.

Emerging concepts and recent advances in basal cell carcinoma.

Totonchy M, Leffell D.

F1000Res. 2017 Dec 4;6:2085. doi: 10.12688/f1000research.11314.1. eCollection 2017. Review.

14.

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.

Chung WJ, Daemen A, Cheng JH, Long JE, Cooper JE, Wang BE, Tran C, Singh M, Gnad F, Modrusan Z, Foreman O, Junttila MR.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10947-E10955. doi: 10.1073/pnas.1708391114. Epub 2017 Dec 4.

15.
16.

Drug Resistance Driven by Cancer Stem Cells and Their Niche.

Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T.

Int J Mol Sci. 2017 Dec 1;18(12). pii: E2574. doi: 10.3390/ijms18122574. Review.

17.

Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.

Kumari A, Ermilov AN, Grachtchouk M, Dlugosz AA, Allen BL, Bradley RM, Mistretta CM.

Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10369-E10378. doi: 10.1073/pnas.1712881114. Epub 2017 Nov 13.

PMID:
29133390
18.

New Opportunities and Challenges to Defeat Cancer Stem Cells.

Ramos EK, Hoffmann AD, Gerson SL, Liu H.

Trends Cancer. 2017 Nov;3(11):780-796. doi: 10.1016/j.trecan.2017.08.007. Epub 2017 Sep 21. Review.

PMID:
29120754
19.

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.

Mirza AN, Fry MA, Urman NM, Atwood SX, Roffey J, Ott GR, Chen B, Lee A, Brown AS, Aasi SZ, Hollmig T, Ator MA, Dorsey BD, Ruggeri BR, Zificsak CA, Sirota M, Tang JY, Butte A, Epstein E, Sarin KY, Oro AE.

JCI Insight. 2017 Nov 2;2(21). pii: 97071. doi: 10.1172/jci.insight.97071. [Epub ahead of print]

20.

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.

Gruber W, Peer E, Elmer DP, Sternberg C, Tesanovic S, Del Burgo P, Coni S, Canettieri G, Neureiter D, Bartz R, Kohlhof H, Vitt D, Aberger F.

Int J Cancer. 2018 Mar 1;142(5):968-975. doi: 10.1002/ijc.31117. Epub 2017 Nov 6.

Supplemental Content

Support Center